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Take home message: Loss to follow up risk is constant throughout MDRTB 28 
treatment globally. ↑risk = men, HIV+, 26-50yrs & standard regime  29 
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30 
Loss-to-follow-up (LFU) of two or more consecutive months contributes to the poor 31 
levels of treatment success in multidrug-resistant tuberculosis (MDR-TB), reported 32 
by TB programmes. We explore the timing when LFU occurs by month of MDR-TB 33 
treatment and identify patient-level risk factors associated with LFU. 34 
We analysed a dataset of individual MDR-TB patient data (5,970 patients from 23 35 
countries). We used Kaplan-Meier survival curves to plot time to LFU and a Cox 36 
proportional hazards model to explore the association of potential risk factors with 37 
LFU. 38 
One-fifth (n=1,282) of patients were recorded as LFU. Median time to LFU was 16 39 
months (IQR=6-18). A sharp increase in rate of LFU at month 18 of treatment was 40 
identified as artefactual from one large cohort. Risk factors associated with LFU were 41 
age (26-35yrs: Hazard Ratio (HR) 1.20; 95% CI 1.04, 1.39 and 36-50yrs: HR 1.28; 42 
95% CI 1.09, 1.49 compared with age 0-25yrs), being male (HR 1.13; 95% CI 1.04, 43 
1.23), HIV positive (HR 1.36; 95% CI 1.02, 1.80) and treatment with a standardised 44 
regimen (individualised treatment had HR 0.55; 95% CI 0.32, 0.93 compared with 45 
standardised regimen). 46 
Both patient and regimen-related factors were associated with LFU which may guide 47 
interventions to improve treatment adherence. 48 
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		49 
Multidrug-resistant tuberculosis (MDR-TB) is a growing challenge to TB treatment 50 
programmes globally. Treatment completion rates remain low at 50% with 16% lost 51 
to follow up (LFU - previously termed “treatment default”)[1-4] – defined as MDR-TB 52 
patients “whose treatment was interrupted for two consecutive months or more”.[5] 53 
Patients who do not complete pulmonary MDR-TB treatment pose a public health 54 
risk of ongoing transmission of resistant, infectious disease as well as a high 55 
likelihood of death for the patient.  56 
Current evidence from MDR-TB treatment cohorts, identifies that LFU is associated 57 
with being male,[6] substance misuse,[6-11] resistance to a high number of anti-TB 58 
drugs, [6, 12, 13] the absence of early culture conversion,[6, 11, 13, 14] poor patient-59 
provider relationships,[8, 10] greater disease severity,[7] HIV co-infection[15] and the 60 
occurrence of drug side effects.[10, 13]  61 
Several studies suggest that the majority of LFU takes place in the early stages of 62 
MDR-TB treatment when patients may still be infectious. The percentage of total 63 
LFU that occurred in the intensive phase (first 6-8 months) of MDR-TB treatment 64 
was 77.8% in the Philippines (total sample size(N)=273, total LFU=91)),[10] 71.1% in 65 
Armenia (N=381, LFU=97),[13] 72.7% in Pakistan (N=186, LFU=33)[16] and 40.8% 66 
in Georgia (N=1,240, LFU=458).[11] The total LFU occurring by six months was 67 
86.9% in India (N=796, LFU=153).[14] In Uzbekistan, median time to LFU was 6 68 
months (N=710, LFU=142).[12]  69 
Several strategies have been attempted by TB programmes to reduce LFU[17], 70 
including providing directly observed treatment (DOT) throughout the course of 71 
treatment,[18] providing patient education and managing smaller numbers of 72 
patients. 73 
To optimise the management of MDR-TB patients, national TB treatment 74 
programmes would benefit from knowing who are at risk of LFU and when it is likely 75 
to occur. Interventions targeted at individuals with these risk factors and these time 76 
points could reduce rates of LFU and ultimately assist in controlling the epidemic. 77 
Analysis to specify the time of LFU more accurately would optimise the timing of 78 
such interventions. Here we are able to use the largest ever multi-country, individual 79 
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MDR-TB dataset, to identify the timing of LFU in the treatment of pulmonary MDR-80 
TB and to identify patient-level risk factors associated with LFU. [1-3] 81 
 82 
	83 
The dataset of the 	

	
84 
 was used for this analysis. This data set includes individual-level 85 
treatment data from 9,153 pulmonary MDR-TB patients from TB clinics or 86 
programmes from 23 countries, reported in 32 previously published observational 87 
studies. Patients had to have received at least one month’s treatment in order to be 88 
included. The patient characteristics and definitions of the variables within the 89 
dataset have been described elsewhere.[1] Permission was not granted for this 90 
analysis, for one cohort of patients included in the original data set. 91 
For our analysis, patients were included if there was authorization of the lead 92 
investigator for each cohort and patients were alive at the point of LFU. Patients 93 
were defined as LFU if their outcome was recorded as ‘defaulted’, ‘transferred out 94 
(with unknown outcome)’ or ‘unknown’ in the dataset, based on the outcome 95 
definitions available at the time data were collected.[19] Time of LFU for each patient 96 
was identified by their recorded duration of treatment in months. The treatment 97 
cohorts included in this analysis used a variety of drug regimens and treatment 98 
lengths, most were 20-24 months. Those with a duration of treatment longer than 24 99 
months (n=800) were truncated at 24 months. Records were excluded if lead 100 
investigators did not give consent for their data to be included or if there was no 101 
record of duration of treatment. We also excluded patient records whose outcome 102 
was death. Although it is possible that some of these patients may have chosen to 103 
stop MDR-TB treatment before death, the dataset did not include this detail so we 104 
decided to exclude all patients who died.  105 
We identified the independent variables from the dataset to include in the analysis 106 
from previous studies where significant associations with LFU had been identified 107 
(see introduction). Variables included in the analysis were: age, sex, HIV co-infection 108 
status, extensive TB disease (defined as Acid Fast Bacillus (AFB) smear positive, or 109 
cavities on chest radiography if no information about AFB-smear was available), type 110 
of regimen (standardised v individualised), previous TB therapy (defined as 111 
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treatment with first-line, or second-line TB drugs for 1 month or more), recorded drug 112 
resistance to pyrazinamide, ethambutol and streptomycin, recorded serious adverse 113 
events and AFB-smear status. We were also interested in variations by national 114 
income and so we distinguished study cohorts from high-income and middle-income 115 
countries within the analysis (according to World Bank classifications).[20] There 116 
were no cohorts from low-income countries. 117 
The proportion of all patients who were LFU are reported. As the data were 118 
negatively skewed we used quantile regression analysis to compare median time to 119 
LFU for subgroups (per independent variable). We then employed Kaplan-Meier 120 
methods to plot survival curves and estimate the unadjusted time to LFU across the 121 
treatment period. To explore this distribution further, we undertook sensitivity 122 
analysis by plotting timing of LFU by each cohort within the data set, comparing 123 
middle-income and high-income countries and by removing one large cohort. Lastly, 124 
a Cox proportional hazards model was created to assess the effects of potential risk 125 
factors on LFU, using adjusted hazard ratios with 95% confidence intervals and the 126 
associated (two-sided) p-values. Patient-level data were considered to be clustered 127 
within study cohorts and so the model used a random-effects, multi-level analysis to 128 
account for this. SAS software (SAS Institute Inc. version 9.4) was used to undertake 129 
the statistical analysis. The original ethics approval for the analysis of anonymised 130 
data for the 	

	
 131 
covered also this secondary analysis and therefore no separate ethics review was 132 
needed. 133 
 134 
135 
136 
137 
Data originated from 23 countries: ten studies were from Asia (four of which were 138 
from South Korea), six from North America, five from Europe, four from Central and 139 
South America, four from former Soviet states, two from South Africa and one from 140 
Iran. The exclusions from the full dataset (n=9,153) were one treatment cohort 141 
without permission to include (n=607), patients with no follow-up time recorded 142 
(n=1,333) or with an outcome of death (n=1,243). Our dataset therefore included 143 
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5,970 patients, of which 1,282 (21.5%) were recorded as LFU. This LFU rate is 144 
comparable with that reported in the full data set (23%).[1] The characteristics of the 145 
patients in our dataset are described in table 1.  146 
 147 
 148 
Table 1 – Characteristics of MDR-TB patients and the median time to loss-to-follow-149 
up 150 
Insert Table 1 here 151 
MDR-TB: multidrug-resistant tuberculosis; LFU: lost to follow-up; IQR: inter-quartile range; HIV: human immunodeficiency virus; 152 
AFB: acid-fast bacillus test 153 
 154 
After six months of treatment, 26% (n=336) of those who were recorded as LFU had 155 
been lost (Fig. 1). At the end of the intensive stage of treatment at 8 months 35% 156 
(n=448) had been lost. By the 12 month stage 44% (n=567) had been lost and by 18 157 
months it was 88% (n=1124).  158 
Figure 1 – Cumulative percentage of LFU* for all MDR-TB patients and for LFU 159 
patients by month of treatment 160 
Insert Fig.1 here 161 
Note: The two sets of data points show the timing of LFU among all MDR-TB patients (n=5,970) and for those that were 162 
recorded as LFU (n=1,243).  *LFU: loss to follow up 163 
 164 
For all patients recorded as LFU, the median time to LFU was 16 months (inter-165 
quartile range (IQR) 6-18 months). The median time to LFU was much lower in some 166 
sub-groups (Table 1): for example, those over 50 years old (median time to LFU 9 167 
months (IQR 5-18), high-income country cohorts (8 months; IQR 5-16), negative HIV 168 
status (11 months; IQR 5-18), individualised treatment regime (7 months; IQR 3-14), 169 
no previous TB treatment (10 months, IQR 6-18) and previous MDR-TB treatment 170 
(12 months; IQR 5-18). Time to LFU also varied by the decade in which cohorts were 171 
treated and the median time was much longer in patients starting treatment in the 172 
latter decade. 173 
 174 
 	
!"#175 
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For all patients recorded as LFU, the rate of LFU occurrence is steady in the first 17 176 
months of treatment (Fig. 2). A substantial change in probability of being LFU then 177 
occurs around month 18 of treatment. We suspected this may have been artefactual 178 
and therefore conducted further analysis (see supplementary material and Fig. 3). 179 
From this we identified a large cohort from South Africa (n=1,789) which appeared to 180 
contribute to this change in probability at 18 months. After removing this large cohort, 181 
the plot of time to LFU in the reduced data set indicates it was indeed responsible 182 
(Fig. 4).  183 
 184 
Figure 2 - Time to Loss-to-Follow-Up after starting MDR-TB treatment for all patients, 185 
using Kaplan-Meier analysis 186 
Insert Fig. 2 here 187 
 188 
Figure 3 – Time to Loss-to-Follow-Up after starting MDR-TB treatment, for patients 189 
by national income category, using Kaplan-Meier analysis 190 
    Insert Fig. 3 here 191 
 192 
Figure 4 - Time to Loss-to-Follow-Up after starting MDR-TB treatment for all patients 193 
(minus a large South African cohort), using Kaplan-Meier analysis (n=4,181)194 
Insert Fig. 4 here195 
196 
$
				
		197 
After adjusting for all other variables in a Cox proportional hazards model, several 198 
risk factors were significantly associated with LFU (Table 2 and Figure 5). Those 199 
aged 26-35 and 36-50 years old had 20% and 28% higher incidence of LFU 200 
respectively (HR 1.20; 95% CI 1.04, 1.39 and HR 1.28; 95% CI 1.09, 1.49 201 
respectively) compared to those aged 0-25 years old. Males had a 13% higher 202 
incidence of LFU (HR 1.13; 95% CI 1.04, 1.23) compared to females. Those with 203 
HIV had a 36% higher incidence of LFU (HR 1.36; 95% CI 1.02, 1.80) compared to 204 
HIV negative patients. Those receiving an individualised treatment regimen had 45% 205 
lower incidence of LFU (HR 0.55; 95% CI 0.32, 0.93) compared with a standardised 206 
regimen. 207 
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 208 
 209 
Table 2 – Risk factors associated with loss-to-follow-up among all MDR-TB patients 210 
(n=5,970) 211 
Insert Table 2 here 212 
MDR-TB: multidrug-resistant tuberculosis; CI: confidence interval; HIV: human immunodeficiency virus; AFB: acid-fast bacillus 213 
test; HIC: high-income country; MIC: middle-income country 214 
215 
Figure 5 – Adjusted hazard ratios of risk factors associated with loss-to-follow-up 216 
among all MDR-TB patients (n=5,970) 217 
Insert Fig. 5 here 218 
 219 
220 
221 
%	222 
Incomplete treatment of MDR-TB is an important driver of continued transmission 223 
and avoidable TB morbidity and mortality worldwide. Using the largest dataset of 224 
individual MDR-TB patients currently available, our study is the most comprehensive 225 
assessment to date of the timing and risk factors for LFU. The overall frequency of 226 
21.5% is similar to that reported by WHO from global TB monitoring[4]. The median 227 
time to LFU was 16 months (IQR 6-18 months). Sub-groups with a higher risk of LFU 228 
were 26-50 year olds, males, those with HIV+ status and those receiving a 229 
standardised treatment regimen.  230 
The timing of LFU for patients in our study is predominantly in the continuation phase 231 
of treatment (months 8–24) with a large change in LFU at 18 months. Further 232 
analysis identified that a large cohort from South Africa (n=1,789) was mainly 233 
responsible for this change, which is likely to be artefactual in nature. The reporting 234 
practices of the TB programme at the time caused many patients to be assigned 235 
LFU at 18 months, even though they may have met the criteria for LFU well before 236 
this date (personal communication with study authors)..  237 
The timing of LFU in our study differs markedly from studies reporting more recent 238 
treatment cohorts, where the majority of LFU tended to be in the initial intensive 239 
phase of treatment (see Introduction). The treatment of all patients in our study 240 
Page 8 of 25European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
predates 2008, compared with these LFU studies of MDR-TB patients which tend to 241 
be more recent (published 2006 – 2015)[7-16]. It is possible that the distribution of 242 
timing of LFU has changed over time. Further research on aggregated data from 243 
more recent cohorts would help to identify if a different pattern exists for timing of 244 
LFU compared with our older cohorts in this study. 245 
Some of the patient-related risk factors associated with LFU which we identify are 246 
similar to those found in previous studies. Being male is a common risk factor for 247 
poor adherence in many health conditions[22] and has been identified in MDR-TB 248 
patients previously[6]. As the majority of MDR-TB patients receiving treatment 249 
globally are male[4] this is an important driver of rates of LFU. This association with 250 
sex is complex[23]. It is difficult to separate individual behaviours and responses to 251 
treatment by males compared to females, from structural factors such as the social 252 
construct of gender identities and the delivery of health care services[24]. For 253 
example, the opening times of TB treatment centres can be incompatible with regular 254 
access from workers in labour markets structured differentially by gender[25]. Being 255 
male may also be associated with attitudes and behaviours shaped by cultural 256 
factors which predispose to interruption (e.g. itinerancy, alcohol use)[24]. Further 257 
qualitative research with MDR-TB patients (particularly men who do not complete 258 
treatment, although they can be difficult to access) could shed light on this complex 259 
area of treatment adherence.  260 
Having co-infection of HIV is a risk factor for LFU in our analysis with MDR-TB 261 
patients. Historically, poor access to anti-retroviral treatment and the lack of co-262 
ordination between HIV and TB treatment programmes have been highlighted as 263 
factors which lead to worse outcomes for those co-infected[26]. In addition, these 264 
patients might develop some other infectious or non-infectious complication, which 265 
precludes continuation of their MDR-TB treatment. Our analysis underlines the 266 
importance of identifying and addressing the particular challenges faced by patients 267 
who are co-infected with HIV, to improve their chance of a successful treatment 268 
outcome. 269 
Better treatment outcomes in children compared with adults have been reported in 270 
co-infected HIV populations[27] and non-HIV populations[28]. An increased risk of 271 
LFU in those aged 26-50 was identified in our analysis. This could be explained by 272 
increased family support offered to younger and older family members with MDR-TB. 273 
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Furthermore, the competing demands of employment and dependents for individuals 274 
in the working age groups could also be influential in their greater risk of LFU[25]. 275 
For several variables in our Cox proportional hazards model, the ‘unknown’ category 276 
was significantly associated with being LFU (resistance to pyrazinamide, resistance 277 
to streptomycin and serious adverse events). Weaker TB treatment programmes 278 
may be the confounding factor, where poorer recording practices and limited efforts 279 
at following up patients are both associated with weaker programmes. 280 
The study has several imitations. The large number (35%) of excluded patient 281 
records, largely as a result of missing data of time to LFU or death, may have 282 
introduced bias in our findings. The data quality was variable, although attempts 283 
have been made to ensure the dataset is as complete as possible. There are likely to 284 
be other artefactual influences on our data set beyond those we identified from the 285 
large South African cohort, which are unaccounted for in our analysis. This dataset is 286 
largely restricted to patients who had received one month or more of treatment. This 287 
could have led to an artefactual prolongation of LFU as patients who would have 288 
been early interrupters were selectively removed from the cohorts. We did not have 289 
data available for some patient variables that we were interested in, such as co-290 
morbid substance misuse or treatment interruptions of less than two consecutive 291 
months. Furthermore, there are likely to be other types of programme-related or 292 
treatment-related risk factors that are associated with LFU which we did not analyse 293 
and which could explain LFU more fully. All datasets pre-date 2008 so these findings 294 
may not generalise to current programme management of MDR-TB. For instance the 295 
use of a standardised 9-11 month regimen recommended by WHO since 2016 in 296 
selected MDR-TB patients has the potential to reduce LFU due to a substantially 297 
shorter duration of treatment than previous MDR-TB regimens.[29]  298 
Although some treatment cohorts in this dataset were from resource-constrained 299 
contexts, none were from low-income countries. Our findings therefore may not 300 
generalise to these settings. We have identified risk factors that are associated with 301 
LFU - further work needs to be done to explore the mechanisms that drive stubbornly 302 
high rates of LFU in all MDR-TB programmes including in low-income settings. For 303 
instance, the presence of co-morbid depression may reduce adherence in MDR-TB 304 
as it does in other health conditions. [22, 30] 305 
Page 10 of 25European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Our study identifies risk factors associated with being LFU which can guide policy 306 
makers to target interventions at those most at risk, such as men of working age. 307 
Treatment programmes should consider how best to maintain engagement with 308 
these men in an approach that is person-centred and accessible at times and in 309 
locations that are convenient for them. In addition, patients with a co-morbid HIV 310 
infection are more at risk of being LFU. The policy rhetoric that highlights the need 311 
for co-ordination of treatment between both diseases must be implemented by TB 312 
and HIV treatment programmes. 313 
314 
&		315 
The call within the global End TB strategy of patient-centred care should be pursued 316 
to address the ongoing issue of LFU. Our findings suggest that MDR-TB treatment 317 
programmes could offer targeted, enhanced support to prevent LFU in men, those of 318 
working age and patients with HIV co-infection. The use of individualised treatment 319 
regimens may also be beneficial to combat LFU. Further research examining the 320 
timing of LFU in more recent treatment cohorts would add to our knowledge of this 321 
important aspect of MDR-TB treatment. 322 
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Analysis of loss to follow up in 5,970 multidrug-resistant pulmonary 
tuberculosis patients 
Ian F. Walker, Oumin Shi, Joseph Hicks, Helen Elsey, Xiaolin Wei, Dick Menzies, Dennis Falzon, Giovanni 
Battista Migliori, Carlos Pérez-Guzmán, Mario H. Vargas, Lourdes García-García, José Sifuentes Osornio, 
Alfredo Ponce-De-León,  Martie van der Walt and James N. Newell
 
 
Supplementary Data ʹ Kaplan-Meier plots by cohort (Combined sample size N=5,970) Shaded areas are 
confidence intervals. 
 
Cohort i ʹ Canada (n=70)     Cohort ii ʹ  USA (n=35) 
                     
 
Cohort iii ʹ  Taiwan (n=120)      Cohort iv ʹ Mexico (n=35) 
                  
 
Cohort v -  South Korea (n=145)     Cohort vi ʹ Hong Kong (n=96) 
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Cohort vii - Italy (n=82)     Cohort viii ʹ  Peru (n=529) 
               
 
Cohort ix -  Mexico (n=33)     Cohort x ʹ Argentina (n=100) 
               
 
Cohort xi -  UK (n=24)     Cohort xii ʹ  Spain (n=21) 
           
 
 
Cohort xiii ʹ  Vietnam (n=144)    Cohort xiv ʹ  Latvia (n=949) 
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Cohort xv - France (n=30)     Cohort xvi ʹ  USA (n=236) 
            
 
Cohort xvii -  Russian Federation (n=577)  Cohort xviii ʹ  South Africa (n=33) 
              
 
Cohort xix ʹ  South Korea (n=130)    Cohort xx ʹ  Japan (n=59) 
             
 
Cohort xxi ʹ  Philippines (n=146)    Cohort xxii ʹ  Iran (n=35) 
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Cohort xxiii ʹ  Estonia (n=253)    Cohort xxiv ʹ  South Africa (n=1,789) 
             
 
Cohort xxv ʹ  The Netherlands (n=41)   Cohort xxvi ʹ  South Korea (n=191) 
               
 
Cohort xxvii ʹ  Uzbekistan (n=67) 
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